Saga Diagnostics secured Medicare coverage for its Pathlight MRD test, enabling ultrasensitive, early detection of breast cancer recurrences to inform treatment decisions. 4D Molecular Therapeutics reported promising 60-week durability data for its diabetic macular edema gene therapy, which reduced injection frequencies, improving patient outcomes. Meanwhile, Cardiff Oncology's PLK1 inhibitor demonstrated efficacy in KRAS-mutated colorectal cancer, though the stock faced volatility. Additionally, ImmuneOnco and Instil Bio’s PD-L1xVEGF bispecific antibody showed encouraging early clinical data for lung cancer, signaling advances in targeted oncology therapies.